⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8275624 | 0.76 | CTSS (0.31) | — | |
| SCHEMBL600923 | 0.76 | DPP4 (0.34) | — | |
| SCHEMBL17660630 | 0.73 | DEGS1 (0.31) | — | |
| SCHEMBL105836 | 0.73 | DEGS1 (0.31) | — | |
| SCHEMBL23581343 | 0.72 | CTSS (0.30) | — | |
| SCHEMBL2200088 | 0.72 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL12474635 | 0.71 | — | — | |
| SCHEMBL74849 | 0.71 | DEGS1 (0.36) | — | |
| SCHEMBL4546673 | 0.71 | — | — | |
| SCHEMBL10121187 | 0.71 | DEGS1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-3143018-B1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-20210052554-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| US-20200268718-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10195181-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3143018-A1 | CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| WO-2009136850-A1 | MUSCARINIC RECEPTOR AGONITS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| EP-1996188-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |